SemaglutidePriceGuide
Semaglutide Price Guide is an educational pricing and comparison resource operated by Premium Health Solutions. Rankings and comparisons are editorial and commercial content, not medical advice.

Comparison

Semaglutide vs liraglutide

The newer weekly GLP-1 versus the older daily one.

Reviewed 2026-06-04 Physician-reviewed How we research

Quick Answer

Liraglutide (Victoza for diabetes, Saxenda for weight) is an earlier GLP-1 receptor agonist requiring a daily injection. Semaglutide is more potent and longer-acting, dosed weekly (injectable), and generally produces greater A1c and weight reductions. Both share GI side effects and the same drug-class cautions. Compounded versions are not FDA-approved.

Key Facts

  • Liraglutide: daily injection (Victoza for diabetes, Saxenda for weight)
  • Semaglutide: weekly injection (Ozempic/Wegovy) or daily oral (Rybelsus)
  • Semaglutide generally produces greater A1c and weight reductions
  • Both: GLP-1 receptor agonists with similar GI side effects
  • Compounded versions are not FDA-approved

The same class, different generations

Both are GLP-1 receptor agonists, but liraglutide was developed first and has a shorter half-life, requiring a daily injection. Semaglutide is more potent and longer-acting, allowing weekly injection (or daily oral).

Effectiveness

Head-to-head and cross-trial data generally show semaglutide produces greater A1c and weight reductions than liraglutide. For weight, Saxenda (liraglutide 3.0 mg daily) typically yields smaller average loss than Wegovy (semaglutide 2.4 mg weekly), and the daily injection is less convenient for many.

Practical considerations

Liraglutide's daily dosing and generally smaller effect have made semaglutide (and semaglutide) the more common choices, though liraglutide remains an option, and cost, availability and tolerance can influence selection. Both require slow titration and share GI side effects and drug-class cautions.

Caveats

This compares the science, not a recommendation. Compounded versions are not FDA-approved. Suitability is a clinical decision.

Frequently asked questions

Is semaglutide better than liraglutide?

Semaglutide is generally more potent and longer-acting, with greater average A1c and weight reductions and weekly (vs daily) dosing. Liraglutide remains an option; choice is individual.

What's the dosing difference?

Liraglutide is injected daily; injectable semaglutide is weekly (with a daily oral form available).

References

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  2. Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
  3. U.S. Food and Drug Administration. Wegovy, Ozempic and Rybelsus (semaglutide) prescribing information. Novo Nordisk.

Citations are for educational reference; this article summarizes published research in plain language and is not medical advice.

Bottom Line

Semaglutide is the newer, more potent, weekly GLP-1 versus liraglutide's older daily option, generally producing greater weight and glucose effects. Both share the same class cautions.

Related from the Journal

Semaglutide vs semaglutide

The newer dual agonist.

How semaglutide works

GLP-1 mechanism.

Oral vs injectable

Semaglutide forms.

Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”
Compare NexLife plans